Skip to main content
. 2021 Aug 4;11(8):e051983. doi: 10.1136/bmjopen-2021-051983

Table 4.

Summary of outcomes for interventions targeting C. difficile

Key outcomes References
42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57
Antimicrobials use (DDD/1000 PDs) ↓310 ↓200 ↓6.58 ↓124 ↓141 ↓34 ↓10.7
Antimicrobials use (% reduction) 11 47 46 72.5–95 22 12 37
Antibiotics cost (↓%) ↓54 ↓24 ↓51
Antimicrobials streamlining (%/week) ↑52
Resistance rates
CD risk/100 000 or/10 000 PDs (postintervention) 12 14 55 60 2.8 170 2.8 11 16 85
CD absolute risk (%) ↓67 ↓46 ↓83 ↓77 ↓31 ↓51 ↑87 ↓5 ↓71 ↓36 ↓71 ↓37
Risk of HCAIs (AR)
↓25 17–25
% reduction in time for start of treatment 64
Time savings (h/1000 admissions) ↓43
Hospital stay
Adherence to infection prevention precautions (%) ↓6 ↑95
Mortality

↓, significant reduction; ↑, significant increase; ⇔, no significant changes (remained the same); ●, outbreak was contained.

AR, absolute risk; CD, Clostridioides difficile; C. difficile, Clostridioides difficile; DDD, daily defined doses; HCAIs, healthcare-associated infections; PD, patient days.